Semaglutide Side Effects: What to Expect and How to Manage Them

A straightforward guide to what you may experience during treatment, how common each side effect is, and proven strategies to manage them.

Common Side Effects (Affects 10–40% of Patients)

The most common side effects are gastrointestinal. They're typically most noticeable during the first 4–8 weeks and during dose increases. Most patients find they improve significantly as the body adjusts.

Nausea (reported in ~44% of patients in STEP trials)

The most frequently reported side effect. Usually mild to moderate and most common in the first 2–4 weeks of each dose increase. What it feels like: a general queasiness, especially after eating. When it starts: within the first week of starting or increasing dose. Duration: typically improves within 2–4 weeks at each dose level. Management: eat smaller meals, avoid fatty/greasy foods, eat slowly, try ginger tea, avoid lying down after meals.

Diarrhea (~30% of patients)

Can occur at any point but most common during dose titration. Usually resolves without intervention. Stay well hydrated if it occurs. Contact your physician if it's severe or persistent — dose adjustment may help.

Constipation (~24% of patients)

The slowed gastric emptying that helps reduce appetite can also slow overall digestion. Management: increase fiber intake (vegetables, whole grains), stay hydrated (64+ oz water daily), consider a fiber supplement, and maintain physical activity. Over-the-counter stool softeners are generally safe — check with your physician.

Vomiting (~24% of patients)

More common during dose escalation periods. If you vomit within 30 minutes of taking other oral medications, consult your physician about timing. Severe or persistent vomiting should be reported — dose reduction may be needed.

Decreased appetite

This is technically a side effect but also the therapeutic mechanism. While reduced appetite is the goal, it's important to maintain minimum nutritional intake. Aim for at least 1,000–1,200 calories daily even if you're not hungry. See our nutrition guide for strategies.

Less Common Side Effects (Affects 5–10% of Patients)

Headache: Usually mild and more common in early treatment. Often related to dehydration — increase water intake before reaching for pain medication.

Fatigue: Can occur during the adjustment period, especially if caloric intake drops significantly. Ensure adequate protein and hydration.

Dizziness: Often related to dehydration or blood sugar changes. Stand up slowly, stay hydrated, and eat regular small meals.

Injection site reactions: Redness, swelling, or itching at the injection site. Rotate injection sites between abdomen, thigh, and upper arm. Usually resolves within a few days.

Acid reflux / heartburn: Slowed gastric emptying can worsen reflux in some patients. Avoid eating close to bedtime, elevate your head while sleeping, and avoid trigger foods (spicy, acidic, fatty).

Serious Side Effects (Rare but Important)

These are uncommon but require immediate medical attention.

Pancreatitis: Severe, persistent abdominal pain that radiates to the back, potentially with nausea and vomiting. Risk is low but real — approximately 0.2–0.3% in clinical trials. Stop medication and seek emergency care if suspected.

Gallbladder problems: Rapid weight loss can increase the risk of gallstones. Symptoms include severe upper right abdominal pain, nausea, and fever. Reported in approximately 1.6% of patients in trials.

Kidney problems: Severe dehydration from vomiting or diarrhea can affect kidney function. Maintain hydration, especially during GI episodes. Report decreased urination or dark urine to your physician.

Allergic reactions: Rare but possible. Seek emergency care for facial swelling, difficulty breathing, severe rash, or rapid heartbeat.

Changes in vision: Patients with diabetic retinopathy should be monitored closely. Report any vision changes to your physician.

When to Call Your Doctor

Why Dose Titration Matters

One of the most important factors in minimizing side effects is proper dose titration — starting at a low dose and gradually increasing over weeks. This is why physician supervision matters. At New Hope Weight Loss, Dr. Sharma starts every patient at the lowest dose and increases only when the patient has tolerated the current dose for at least 4 weeks. This slow, methodical approach significantly reduces the severity and frequency of GI side effects compared to aggressive dosing schedules.

Frequently Asked Questions

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded medications are not FDA-approved products.